Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

Leukemia. 2020 Mar;34(3):924-928. doi: 10.1038/s41375-019-0597-3. Epub 2019 Oct 14.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdomen / pathology
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Humans
  • Immunotherapy / adverse effects*
  • Kaplan-Meier Estimate
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Lymph Nodes / pathology
  • Lymphadenopathy / etiology*
  • Male
  • Middle Aged
  • Neoplasm, Residual / drug therapy*
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Treatment Outcome